Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENTIATE: BBI-355 in Advanced Solid Tumors
NCT05827614Phase 1Terminated
- Sponsor
- Boundless Bio
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of bbi-355 in solid tumor (5 arms), sponsored by Boundless Bio. Primary endpoints: Treatment Emergent Adverse Events and Maximum Tolerated Dose and/or Recommended Phase 2 Dose. Started Mar 2023; status: terminated.
02
Drugs
bbi-355
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05827614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827614.